The Top 5 Biosimilars Articles for the Week of June 10
The Center for Biosimilars® recaps the top stories for the week of June 10, 2019.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of June 10.
Number 5: The American Medical Association has issued a call for intensified oversight of the pharmacy benefit manager industry.
Number 4: In 3 late-breaking poster presentations at the American Diabetes Association’s 79th Scientific Sessions, researchers presented data on Sanofi’s proposed insulin aspart biosimilar.
Number 3: During the European League Against Rheumatism Annual European Congress of Rheumatology, multiple research teams shared real-world evidence on biosimilar etanercept, SB4.
Number 2: A research letter in JAMA Internal Medicine raises the question of whether there is room for increased FDA transparency about regulatory filings.
Number 1: Experts weighed in on the Biosimilars Forum’s policy proposals that the group says could save the United States billions.
Finally, last week, our e-newsletter asked whether you think other payers will follow UnitedHealthcare’s lead in preferring reference pegfilgrastim over biosimilar options.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
